BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 30586620)

  • 1. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy.
    Frey N; Porter D
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):e123-e127. PubMed ID: 30586620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
    Frey NV; Porter DL
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):567-572. PubMed ID: 27913530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report.
    Xiao X; He X; Li Q; Zhang H; Meng J; Jiang Y; Deng Q; Zhao M
    Clin Cancer Res; 2019 Jan; 25(1):29-34. PubMed ID: 30322878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
    Lee DW; Santomasso BD; Locke FL; Ghobadi A; Turtle CJ; Brudno JN; Maus MV; Park JH; Mead E; Pavletic S; Go WY; Eldjerou L; Gardner RA; Frey N; Curran KJ; Peggs K; Pasquini M; DiPersio JF; van den Brink MRM; Komanduri KV; Grupp SA; Neelapu SS
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):625-638. PubMed ID: 30592986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC].
    Tudesq JJ; Yakoub-Agha M; Bay JO; Courbon C; Paul F; Picard M; Pochon C; Sterin A; Vicente C; Canet E; Yakoub-Agha I; Moreau AS
    Bull Cancer; 2023 Feb; 110(2S):S116-S122. PubMed ID: 34895696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
    Bhaskar ST; Patel VG; Porter DL; Schuster SJ; Nastoupil LJ; Perales MA; Tomas AA; Bishop MR; McGuirk JP; Maziarz RT; Chen AI; Bachanova V; Maakaron JE; Riedell PA; Oluwole OO
    Blood Adv; 2023 Sep; 7(17):4765-4772. PubMed ID: 36508286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy.
    Gazeau N; Liang EC; Wu QV; Voutsinas JM; Barba P; Iacoboni G; Kwon M; Ortega JLR; López-Corral L; Hernani R; Ortiz-Maldonado V; Martínez-Cibrian N; Martinez AP; Maziarz RT; Williamson S; Nemecek ER; Shadman M; Cowan AJ; Green DJ; Kimble E; Hirayama AV; Maloney DG; Turtle CJ; Gauthier J
    Transplant Cell Ther; 2023 Jul; 29(7):430-437. PubMed ID: 37031746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management Principles Associated With Cytokine Release Syndrome.
    Baer B; Dudley CV; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.
    Le RQ; Li L; Yuan W; Shord SS; Nie L; Habtemariam BA; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Aug; 23(8):943-947. PubMed ID: 29622697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of cytokine release syndrome related to CAR-T cell therapy.
    Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
    Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of early tocilizumab intervention on patients with cytokine release syndrome following chimeric antigen receptor T cell therapy].
    Zhou LL; Ye SG; Li P; Tang XC; Liang AB
    Zhonghua Xue Ye Xue Za Zhi; 2023 Dec; 44(12):1022-1026. PubMed ID: 38503526
    [No Abstract]   [Full Text] [Related]  

  • 13. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
    Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
    Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
    De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
    Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
    Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
    J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.
    Zhu F; Wei G; Zhang M; Zhao H; Wu W; Yang L; Hu Y; Huang H
    Cell Transplant; 2020; 29():963689720919434. PubMed ID: 32314613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.
    Wang X; Zhao L; Wang J; Yao Y; Wang J; Ji S; Hua T; Wang S; Cheng H; Shi M; Li Z; Zeng L; Zheng J; Xu K; Cao J
    Front Immunol; 2022; 13():814548. PubMed ID: 35572513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy.
    Pu Y; Zhao Y; Qi Y; Liu Y; Zhang M; Xiao X; Lyu H; Meng J; Zhu H; Xu K; Han W; Zhao M
    Int Immunopharmacol; 2024 Mar; 130():111761. PubMed ID: 38422769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.